TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following criteria to be eligible for enrollment in this study:~* Patient is an ambulatory male or female (if female, nonpregnant) and is at least 18 years old at the Screening Visit.~* Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) while taking standard PPI therapy.~* Patient has evidence of pathological acid reflux.~* Female patients must not be pregnant and must agree to avoid pregnancy for the duration of the study.~* Patient must comply with study procedures.~Exclusion Criteria:~Patients who meet any of the following criteria will not be eligible to participate in the study:~* Patient has a history of complete lack of GERD symptom response to PPI therapy.~* Patient has a significant medical or surgical history including conditions that would impact drug absorption or metabolism (such as bowel obstruction, poorly controlled diabetes, gastroparesis, hiatal hernia).~* Patient reports pain or burning behind the breastbone or in the center of the upper stomach as his or her predominant symptom at the Screening Visit.~* Patient has received an investigational drug during the 30 days before the Screening Visit, or is planning to receive another investigational drug or use an investigational device at any time during the study.~NOTE: Other inclusion and exclusion criteria apply, per the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1500 mg IW-3718 BID + PPI (Type: EXPERIMENTAL): Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
- Placebo + PPI (Type: PLACEBO_COMPARATOR): Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Preoperative Virtual Reality Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. The child is between the age of 7 and 13 years~2. The child is undergoing an elective surgical procedure under general anesthesia~3. The child understands Swiss German~4. The parent(s) understand(s) German~5. The parent(s) possess a smart phone~6. Internet access is given~7. The patient information has been explained~8. Informed Consent is signed~Exclusion Criteria:~1. The child has a hearing impairment~2. The child has neurologic disorder~3. The child requires postoperative intensive care~4. The child has previous experience of anesthesia~5. American Society of Anesthesiologists (ASA) score of III or greater

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Orthopaedic Intervention group (Type: EXPERIMENTAL): In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
- Orthopaedic Control group (Type: NO_INTERVENTION): Gets written and oral preparation for surgery
- Urologic Intervention group (Type: EXPERIMENTAL): In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
- Urologic Control group (Type: NO_INTERVENTION): Gets written and oral preparation for surgery
- General Paediatric Surgery Intervention group (Type: EXPERIMENTAL): In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
- General Paediatric Surgery Control group (Type: NO_INTERVENTION): Gets written and oral preparation for surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic fibrosis patients homozygous for the F508del mutation as confirmed by a genetic test~* Aged 14 years and older~* Male and female~* FEV1 \>50% of predicted normal~Exclusion Criteria:~* Acute respiratory tract infection or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of visit 1~* Any condition prohibiting the correct measurement of the NPD~* Active or passive smoking~* Planned treatment or treatment with another investigational drug or therapy within 1 month prior to randomisation

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- baseline (Type: NO_INTERVENTION): visit 1
- Vardenafil (Type: ACTIVE_COMPARATOR): nasal instillation of Vardenafil ( visit 2 or 3)
- Placebo (Type: PLACEBO_COMPARATOR): Nasal instillation of placebo (visit 3 or 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed pregnancy;~* 18 years or older;~* Two or more unexplained pregnancy loss before the 10th week of gestation, AND/OR one or more unexplained pregnancy loss at or beyond the 10th week of gestation;~* One or more APS laboratory criteria present, according to the revised Sapporo criteria;~Exclusion Criteria:~* Greater than 11 weeks +6 days gestational age at time of randomization;~* Indication(s) for prophylactic or therapeutic-dose anticoagulation;~* Contraindication to heparin or aspirin;~* Received 7 or more doses of LMWH;~* Previous participation in the trial;~* Geographic inaccessibility;~* Refused consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care Arm (Type: ACTIVE_COMPARATOR): Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
- Experimental Arm (Type: EXPERIMENTAL): Open-label low-dose Aspirin 81 mg daily from randomization until delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FAST as a Treatment for Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of moderate obstructive sleep apnea (AHI 5-30/hour) measured within 12 months prior to the planned procedure~* Age \>/= 20 and \>/= 65~* Body Mass Index ,/= 32 (kg/m\^2)~* Patient offered CPAP and has refused of failed to continue CPAP treatment or is not compliant with CPAP~* Signed informed consent to participate in this study~Exclusion Criteria:~* Prior OSA surgery~* Active systemic infection~* Allergy to any medication used during implantation~* Previous history of neck or upper respiratory tract~* Significant dysphagia or speech disorder~Anatomical~* Identified obvious palatal stenosis~* Enlarged tonsils (3+)~* Anatomy unable to accommodate the implant~Other~* Other medical, social, or psychological problems that , in the opinion of the investigator, precludes the patient from receiving this treatment and the procedures and evaluations pre- and post-treatment~* Enrollment in another pharmacological or medical device study that may effect or bias the results of this clinical study~* Unable and/or not willing to comply with treatment follow-up requirements~* Pregnancy (Female subjects of childbearing potential must have a negative pregnancy test prior to enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tongue suspension (Type: EXPERIMENTAL): Tongue-based suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Seroquel XR in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient meets the DSM-IV criteria for schizophrenia~* Patient has a PANSS total score ≥ 70 at baseline~* Patient has a CGI-S score of ≥ 4(moderately ill) at baseline~* Patient is healthy on the basis of physical examination and vital signs at baseline~Exclusion Criteria:~* Positive urine drug screen for Opiates, amphetamine, barbiturate, cocaine, cannabis, or ecstasy abuse~* Has history of neuroleptic malignant syndrome, seropositive for anti-HIV, hepatitis B or C virus antigen~* Patient with unstable or inadequately treated Diabetes Mellitus~* Use of potent cytochrome P450 inhibitors or inducer within 14 days before baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas, ampulla of Vater, or distal bile duct~  * Locally advanced disease~ * Medically inoperable, unresectable, or borderline resectable disease~    * No previously resected disease (i.e., status post-pancreaticoduodenotomy)~* No non-adenocarcinoma, adenosquamous carcinoma, islet cell carcinoma, cyst adenoma, cystadenocarcinoma, carcinoid tumor, or duodenal carcinoma~* No lesions in the tail of the pancreas and/or splenic artery/vein involvement/encasement~* No recurrent or metastatic (M1) disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* WBC \> 3,000/μL~* Platelet count \> 100,000/μL~* Bilirubin ≤ 2 mg/dL~* SGOT \< 5 times upper limit of normal (ULN)~* Creatinine \< 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Adequate oral nutrition (e.g., ≥ 1,500 calories/day, stable weight for ≥ 2 weeks, and ≤ 5% weight loss)~* No active malignancy within the past 3 years, except cervical carcinoma in situ or nonmelanoma skin cancer that has been removed~* No severe, active comorbidity, including any of the following:~  * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~ * Transmural myocardial infarction within the past 6 months~ * Acute bacterial or fungal infection requiring IV antibiotics at the time of study registration~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within the past month or precluding study therapy at the time of study registration~ * Active hepatitis, decompensated cirrhosis, or clinically significant liver failure~ * Other severe comorbid condition, as determined by the principal investigator~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy~* No prior radiotherapy to any upper abdominal site~* No concurrent prophylactic colony-stimulating factors during radiotherapy~* No concurrent warfarin~* No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, surgery for cancer, or experimental therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy plus gemcitabine (Type: EXPERIMENTAL): Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ischemic Stroke and Early Vertical Positioning (SEVEL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Persistent neurological impairment at the participated time, related to an ischemic stroke defined by a sudden neurological deficit. The neurological deficit must not accompany hemorrhage on cerebral tomodensitometry which occurs on the same day or the day previous to the participation~* Patient hospitalized in Neurology department on the day of the participation~* Patient affiliated to the social security~Exclusion Criteria:~* Malignant cerebral infarction, loss of consciousness, comatose with GCS under 13, cerebral herniation, life- threatening infarction.~* Minor neurological deficit defined by isolated facial palsy, dysarthria, hemianopia, sensitive impairment, or every clinical condition that let the physician thinks that the stay in the hospital would be less than 72 hours.~* Known intracranial stenosis above 50% linked to the current infarction~* History of orthostatic neurological degradation~* Vomiting~* Deep venous thrombosis or suspicion of.~* Patients displaying a loss of autonomy with a Rankin score \>3 previous to stroke onset.~* Patient's refusal~* Patient under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early vertical positioning (Type: ACTIVE_COMPARATOR): None
- Progressively vertical positioning (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who are treated with TREDAPTIVE tablet within current local label for the first time~* Participants with primary hypercholesterolemia or mixed dyslipidemia~* Participants who are treated with TREDAPTIVE for more than or equal to 24 weeks will be included in long-term surveillance~* Special participants with known hepatic disorder or renal disorder, participants 65 years old or older, participants younger than 19 years old, and pregnant woman will be evaluated if collected.~Exclusion Criteria:~* Participant who is treated with TREDAPTIVE tablet before contract and out of enrollment period~* Participant who has a contraindication to TREDAPTIVE tablet according to the current local label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: None): Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Spironolactone in Patients With Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged over 18 years~* Hypertension (essential or secondary) managed in Sheffield Hypertension Clinic or general practice or both.~* Blood pressures not adequately controlled (systolic blood pressure (SBP) \>140 mmHg and/or diastolic blood pressure (DBP) \>85 mmHg in clinic and on ambulatory blood pressure monitoring) despite treatment with the maximum tolerated dose of three antihypertensive agents.~* Additional antihypertensive treatment deemed appropriate by the patients' doctor.~* Patients' current antihypertensive treatment includes a thiazide diuretic and at least one of a beta-blocker, angiotensin converting enzyme inhibitor or angiotensin II receptor antagonist.~Exclusion Criteria:~* Definite indication or contraindication for spironolactone~* Known Conn's syndrome (definite indication for spironolactone)~* Heart failure NYHA class III or IV (definite indication for spironolactone)~* Known hepatic failure or significant cirrhosis~* Known pregnancy or women planning pregnancy~* Women of child bearing potential not using adequate contraceptive methods~* Serum creatinine \> 221µmol/l~* Serum Potassium \> 5.0mmol/l~* Clinic blood pressure or daytime ambulatory blood pressure \>240/120

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TECR & ECM Placement for Esophageal High Grade Dysplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 18 years of age and no more than 80 years of age.~2. Have an established diagnosis of HGD~   a. Specific diagnosis and grading will be determined by pathology review of biopsy tissue collected during baseline EGD as part of a patient's standard of care.~3. Have no evidence of lymphovascular invasion.~4. Have no lymph node or other metastatic involvement based on EUS and FDG-PET/CT.~5. Diameter of affected tissue must warrant circumferential excision a. Subjects must have biopsy confirmed HGD in three of four esophageal quadrants at two levels spaced two centimeters apart (minimum of 6/8 biopsies indicating HGD). If two biopsies are normal (contain no HGD) they must be located on separate levels in two different quadrants.~5. Must be an appropriate or reasonable surgical candidate. 6. Have demonstrated an understanding and signed an approved informed consent form for participation in this study.~Exclusion Criteria:~1. Have lesions into or deeper than mucosal layer (superficial (T1a) Esophageal adenocarcinoma).~   a. Those requiring endoscopic submucosal dissection (ESD) are not eligible for this study~2. Have presence of lymphovascular invasion.~3. Require resection length longer than 10 cm.~4. Have any lymph node or other metastatic involvement based on EUS and FDG-PET/CT.~5. Have history of any kind of previous esophageal surgery (i.e. anti-reflux surgery).~6. Are pregnant or planning to become pregnant.~7. Have coagulation disorders.~8. Have a known hypersensitivity to porcine-based materials.~9. Have an uncontrolled comorbid medical condition that would adversely affect participation in the trial.~10. Has a clinically significant psychological illness that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.~11. Are unable or unwilling to provide informed consent and/or fulfill the protocol follow-up requirements.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TECR & ECM (Type: EXPERIMENTAL): Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 3, 4 and 5 chronic kidney disease (not on dialysis)~* Hyperlipidemia requiring cholesterol lowering therapy~* Aged 18 to 80 years old~* Ability to provide informed consent~Exclusion Criteria:~* Patients requiring multiple cholesterol reducing agents~* Patients with neovascularization present, such as neoplasm, active wounds, or significant retinopathy~* Patients with contraindications or allergy to statins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues